These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 38594095)
1. SOX17: escape route from immune destruction in early CRC. Papavassiliou KA; Adamopoulos C; Papavassiliou AG Trends Mol Med; 2024 Jul; 30(7):609-611. PubMed ID: 38594095 [TBL] [Abstract][Full Text] [Related]
2. SOX17 enables immune evasion of early colorectal adenomas and cancers. Goto N; Westcott PMK; Goto S; Imada S; Taylor MS; Eng G; Braverman J; Deshpande V; Jacks T; Agudo J; Yilmaz ÖH Nature; 2024 Mar; 627(8004):636-645. PubMed ID: 38418875 [TBL] [Abstract][Full Text] [Related]
3. SOX17 orchestrates immune evasion in early colorectal adenomas and cancers. Pei B; Yang H; Zhou F Immunology; 2024 Oct; 173(2):422-424. PubMed ID: 39039976 [No Abstract] [Full Text] [Related]
4. The dual role of SOX17 in the occurrence and development of early colorectal cancer. Su X; Shentu J; Chen R; Duan S Mol Biomed; 2024 Sep; 5(1):38. PubMed ID: 39279027 [No Abstract] [Full Text] [Related]
5. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Zhang W; Glöckner SC; Guo M; Machida EO; Wang DH; Easwaran H; Van Neste L; Herman JG; Schuebel KE; Watkins DN; Ahuja N; Baylin SB Cancer Res; 2008 Apr; 68(8):2764-72. PubMed ID: 18413743 [TBL] [Abstract][Full Text] [Related]
6. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes. Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma. Li JY; Han C; Zheng LL; Guo MZ Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318 [TBL] [Abstract][Full Text] [Related]
8. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122 [TBL] [Abstract][Full Text] [Related]
9. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer. Li L; Yang WT; Zheng PS; Liu XF Cell Death Dis; 2018 Jul; 9(7):741. PubMed ID: 29970906 [TBL] [Abstract][Full Text] [Related]
10. The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Li Y; Lv Z; He G; Wang J; Zhang X; Lu G; Ren X; Wang F; Zhu X; Ding Y; Liao W; Ding Y; Liang L Oncotarget; 2015 Apr; 6(11):9099-112. PubMed ID: 25868860 [TBL] [Abstract][Full Text] [Related]
11. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. Hsu HC; Liu YS; Tseng KC; Yang TS; Yeh CY; You JF; Hung HY; Chen SJ; Chen HC J Cancer Res Clin Oncol; 2015 Jan; 141(1):11-21. PubMed ID: 25060070 [TBL] [Abstract][Full Text] [Related]
12. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Kuo IY; Wu CC; Chang JM; Huang YL; Lin CH; Yan JJ; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC Int J Cancer; 2014 Aug; 135(3):563-73. PubMed ID: 24407731 [TBL] [Abstract][Full Text] [Related]
13. Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier. Corada M; Orsenigo F; Bhat GP; Conze LL; Breviario F; Cunha SI; Claesson-Welsh L; Beznoussenko GV; Mironov AA; Bacigaluppi M; Martino G; Pitulescu ME; Adams RH; Magnusson P; Dejana E Circ Res; 2019 Feb; 124(4):511-525. PubMed ID: 30591003 [TBL] [Abstract][Full Text] [Related]
14. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer. Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583 [TBL] [Abstract][Full Text] [Related]
15. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Du YC; Oshima H; Oguma K; Kitamura T; Itadani H; Fujimura T; Piao YS; Yoshimoto T; Minamoto T; Kotani H; Taketo MM; Oshima M Gastroenterology; 2009 Oct; 137(4):1346-57. PubMed ID: 19549530 [TBL] [Abstract][Full Text] [Related]
16. CUX2/KDM5B/SOX17 Axis Affects the Occurrence and Development of Breast Cancer. Li L; Zhu G; Tan K; Jiang L; Li Y; Zhu X; Lin Z; Zhang X; Chen J; Ma C Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35881915 [TBL] [Abstract][Full Text] [Related]
17. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer. Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA‑21‑5p promotes epithelial to mesenchymal transition by targeting SRY‑box 17 in endometrial cancer. Wang C; Li Q; He Y Oncol Rep; 2020 Jun; 43(6):1897-1905. PubMed ID: 32236579 [TBL] [Abstract][Full Text] [Related]
19. SOX17 is a tumor suppressor in endometrial cancer. Zhang Y; Bao W; Wang K; Lu W; Wang H; Tong H; Wan X Oncotarget; 2016 Nov; 7(46):76036-76046. PubMed ID: 27738313 [TBL] [Abstract][Full Text] [Related]
20. 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1. Li W; Wu D; Niu Z; Jiang D; Ma H; He H; Zuo X; Xie X; He Y Int J Mol Med; 2016 Oct; 38(4):1047-54. PubMed ID: 27513557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]